ABHD2

Across TCGA pan-cancer cohorts, ABHD2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ABHD2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ABHD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ABHD2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ABHD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.970	0.698	.001	38	view →
LUAD	DFS	Quartile	All	0.491	1.000	.034	8	view →
LSCC	DFS	Median	All	0.901	0.972	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ABHD2–PDAC (OS)

Open the PDAC breakdown →